Health & Diseases

Heart Failure in Dogs: Symptoms, Diagnosis, and Treatment

Heart failure describes a condition in which the heart is no longer able to adequately supply the body with blood (and thus oxygen) — despite compensatory mechanisms. The consequences are signs of congestion: pulmonary edema (in left heart failure), ascites and peripheral edema (in right heart failure), or both.

Heart Failure in Dogs: Symptoms, Diagnosis, and Treatment

What is heart failure in dogs?

Heart failure refers to a condition in which the heart is no longer able to supply the body with sufficient blood (and thus oxygen)—despite compensatory mechanisms. The consequences are signs of congestion: pulmonary edema (in left-sided heart failure), ascites, and peripheral edema (in right-sided heart failure), or both.

The most common underlying heart conditions in dogs are mitral valve disease (MMVD) in small breeds and dilated cardiomyopathy (DCM) in large breeds. Heart failure is a syndrome, not a single disease.

Background + Scientific Context

Boswood (2010, JVIM, PubMed 20494131) investigated cardiac biomarkers—particularly NT-proBNP—in dogs with various stages of heart disease: NT-proBNP is proportional to myocardial tension and reliably correlates with the severity of heart failure. Elevated NT-proBNP levels distinguish cardiac from respiratory diseases and allow for prognosis assessment without immediate echocardiography. For clinical practice: NT-proBNP is a useful screening tool prior to echocardiography.

Tidholm et al. (2009, JVIM, PubMed 19175847) monitored dogs with DCM via echocardiography for more than five years: Annual echocardiographic follow-up examinations in predisposed breeds (Doberman, Boxer, Irish Wolfhound) enabled early diagnosis of preclinical stages. Occult DCM (no clinical symptoms, but echocardiographic changes) is treatable—early intervention improves the prognosis.

Oyama et al. (2008, JVIM, PubMed 18947327) demonstrated the prognostic value of natriuretic peptides in dogs at various stages of heart disease: NT-proBNP and ANP levels rose progressively with disease severity and correlated with cardiac mortality. Serial measurements can provide an objective assessment of treatment success and disease progression.

Vitomalia-Position

Heart failure in dogs is often easily treatable—but the timing of the diagnosis determines the prognosis. Dogs that undergo annual echocardiography (especially those of predisposed breeds) have a better chance of receiving early intervention. Heart failure is not an inevitable consequence of aging.

When does heart failure become a concern in dogs?

  • For predisposed breeds over 5 years of age: annual cardiac checkup recommended
  • If symptoms occur: intolerance to physical exertion, rapid fatigue, coughing, fainting, ascites
  • If a heart murmur is present: Monitoring according to the ACVIM staging system
  • For dogs undergoing cardiac treatment: regular laboratory tests (electrolytes, kidney function)
  • Before anesthesia in older dogs: cardiac screening is recommended

Practical application

Clinical signs by stage:

Stadium Clinical signs Therapy
The Breed predisposed to the condition; no findings Control
Business/Tourist Visa Heart murmur, ± cardiac enlargement Pimobendan (B2), Monitoring
C Cough, shortness of breath, fatigue Pimobendan + Furosemide + ACE inhibitor
The Refractory heart failure, pulmonary edema Intensive care, palliative care

Diagnostic tools: - Auscultation: heart murmurs, arrhythmias - X-ray: cardiac size (VHS), pulmonary edema, pleural effusion - Echocardiography: cardiac function, valve assessment, filling pressures - NT-proBNP: Biomarker, Screening, and Follow-up - ECG: Arrhythmias, especially in dogs with DCM

Common Mistakes & Myths

  • “A heart murmur does not necessarily mean heart failure.” Heart murmurs can be asymptomatic for years—staging determines the need for treatment. A murmur alone is not an emergency.
  • “Heart failure is incurable—there’s nothing you can do about it.” Heart failure is incurable, but it can be effectively managed with medication. Treated dogs live significantly longer and enjoy a better quality of life than untreated dogs.
  • “My dog doesn’t need regular heart checkups.” Preclinical heart disease shows no symptoms—only echocardiography can detect the early stages. Early intervention has been shown to alter the course of the disease.

Current State of Research (2026)

Gene therapy approaches for MMVD are currently in early-stage clinical trials. New loop diuretics and RAAS modulators are being investigated for heart failure in dogs. Wearable ECG devices (Holter monitors) for home monitoring of arrhythmias (in Boxers, Dobermans) are available to pet owners. Telemedicine cardiology consultations enable remote evaluation of echocardiograms.

Frequently Asked Questions

How long can a dog with heart failure live?

This depends on the underlying condition, the time of diagnosis, and the treatment. Well-managed dogs with stage C MMVD often live for 1–3 years with a good quality of life. Dogs with DCM have a median survival of 6–18 months after diagnosis, depending on the breed and when treatment begins. Early diagnosis and consistent treatment can prolong both.

What medications are prescribed for dogs with heart failure?

Standard treatment regimen for Stage C: Pimobendan (cardiac support + vasodilation), Furosemide (diuretic), ACE inhibitor (Enalapril/Ramipril, RAAS inhibition), Spironolactone (additional diuretic effect). Dosage must always be adjusted by a veterinarian—do not self-medicate.

Can I adjust my diet if I have heart failure?

Reducing sodium intake (low-sodium diet) is recommended for advanced heart failure—but not in the early stages (as it increases stress on the RAAS). Avoid cachexia: adequate protein intake is important. Specific cardiac diets are available—consult your veterinarian for recommendations.

Related terms

Sources & Further Reading

  1. Boswood, A. (2010). Biomarkers in cardiovascular disease: beyond natriuretic peptides. Journal of Veterinary Internal Medicine, 23(6), 1507–1508. https://pubmed.ncbi.nlm.nih.gov/20494131/

  2. Tidholm, A., Häggström, J., Borgarelli, M., & Tarducci, A. (2009). Canine idiopathic dilated cardiomyopathy. Part I: Aetiology and pathophysiology. Veterinary Journal, 179(3), 320–332. https://pubmed.ncbi.nlm.nih.gov/19175847/

  3. Oyama, M. A., Fox, P. R., Rush, J. E., Rozanski, E. A., & Lesser, M. (2008). Clinical utility of serum N pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. Journal of Veterinary Internal Medicine, 22(3), 590–597. https://pubmed.ncbi.nlm.nih.gov/18947327/

Wissenschaftliche Einordnung

Boswood (2010, JVIM, PubMed 20494131) investigated cardiac biomarkers—specifically NT-proBNP—in dogs with various stages of heart disease: NT-proBNP is proportional to cardiac wall stress and reliably correlates with the severity of heart failure. Elevated NT-proBNP levels differentiate cardiac from respiratory diseases and allow for prognosis without immediate echocardiography. For practical application: NT-proBNP is useful as a screening tool before echocardiography.

Tidholm et al. (2009, JVIM, PubMed 19175847) followed dogs with DCM echocardiographically for over five years: Annual echocardiographic check-ups in predisposed breeds (Doberman, Boxer, Irish Wolfhound) allowed for early diagnosis of preclinical stages. Occult DCM (no clinical symptoms, but echocardiographic changes) is treatable—early intervention improves prognosis.

Oyama et al. (2008, JVIM, PubMed 18947327) demonstrated the prognostic value of natriuretic peptides in dogs with various stages of heart disease: NT-proBNP and ANP progressively increased with disease severity and correlated with cardiac mortality. Serial measurements can objectively assess treatment success and disease progression.